Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
TUCSON, Ariz., April 17, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that, on April 12, 2017, the company received formal notice from The NASDAQ Stock Market LLC indicating that the Nasdaq Hearings Panel had granted the Company's request to transfer the listing of HTG’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market based upon HTG’s compliance with all requirements for continued listing on the latter market. The intra-market transfer took effect upon the open of trading this morning, Monday, April 17, 2017.
“We are pleased to have this listing compliance matter behind us, and continue our focus on building long-term shareholder value,” stated TJ Johnson, President and Chief Executive Officer of HTG.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expected timing for the transfer of our common stock to The Nasdaq Capital Market. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks described in our our Annual Report on Form 10-K for the year ended December 31, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: [email protected]
